The Food and Drug Administration yesterday updated two guidances for the temporary compounding of certain drugs used to treat COVID-19 patients.

The guidance for temporary compounding of certain drugs for outsourcing facilities now includes information to help hospitals determine which facilities are covered by the policy, and clarifies policies for testing both container-closures and product stability. It also says FDA will not take action against outsourcing facilities for filling drug orders for copies of FDA-approved products.

In addition, FDA updated guidance for temporary compounding of certain drugs by pharmacy compounders to include reporting to FDA any adverse events associated with drugs they compounded. 

Related News Articles

Headline
The Centers for Disease Control and Prevention updated its page on COVID-19 transmission to clarify other types of spread beyond person to person, such as by…
Headline
The Food and Drug Administration yesterday updated guidance to spur wider availability of alcohol-based hand sanitizers during the COVID-19 pandemic. The…
Headline
The Health Resources and Services Administration today awarded $20.3 million to increase the number of fellows at accredited addiction medicine and addiction…
Headline
The Centers for Medicare & Medicaid Services yesterday implemented several new infection control actions to combat COVID-19 in nursing homes. One…
Headline
The AHA today asked the Department of Health and Human Services to distribute substantial additional emergency funds to hospitals and health systems in an…
Headline
An estimated 9.5% of U.S. residents, or 30.7 million people, lacked health insurance when surveyed in the first six months of 2019, according to preliminary…